tbuckley/cabot-search huggingface dataset:
Association of NBS1 expression with improved pathologic complete response rate in HER2-overexpressing breast cancer.
Authors: Fatma Sen, Ekrem Yavuz, Gulcin Yegen, Hasan Karanlik, Sitki Tuzlali, Adnan Aydiner
Journal: Journal of Clinical Oncology (2013)

e11534 Background: Our aim was to investigate potential correlation between expression levels of Nijmegen breakage syndrome1 (NBS1) protein and phosphatidylinositol-3 kinase (PI3K) and pathologic complete response (pCR) rate to neoadjuvant treatment in locally advanced HER2+ breast cancer. We also assess possible association between NBS1 and PI3K expressions. Methods: Totally 42 patients (median age 49 years), received neoadjuvant treatment due to locally advanced HER2+ breast cancer, were included. Immunohistochemical analyses were performed on paraffin sections, obtained during initial diagnosis. Paraffin sections were stained with anti-NBS1 (P95-NBS1 antibody, Y112, ab32074) and anti-PI3K (PI3-Kinase p85 alpha+gamma antibody, ab741369) antibodies to determine positivity of related proteins. Results: NBS1 protein loss was detected in 19 (%45) patients whereas p85 loss was shown in 25 (%60). There was no initial clinicopathologic variable predicting pCR. Fifteen of 30 patients, received neoadjuvant trastuzumab, had pCR, whereas only 1 of 12 patients, not received trastuzumab, achieved pCR (P = 0.012). p85 loss did not predict treatment response, however NBS1 protein expression positively correlated with increased response rate to neoadjuvant treatment (P = 0.007). Conclusions: NBS1 protein expression associates with increased pCR rate in HER2+ breast cancer. However, P85 positivity did not associate with pCR rate or NBS1 overexpression.
TCT-657 Comparison of Subsequent Neoatherosclerotic Findings at Mid-Term Follow-Up Optical Coherence Tomography Between Second- and Third-Generation Drug-Eluting Stent Implantation
Authors: Toshiya Miura, Shinjo Sonoda, Kounosuke Inoue, Masaru Araki, Yutaka Otsuji
Journal: Journal of the American College of Cardiology (2019)
Progress Toward Poliovirus Containment Implementation — Worldwide, 2018–2019
Authors: Daphne B. Moffett, Anna Llewellyn, Harpal Singh, Eugene Saxentoff, Jeffrey Partridge, Maria Iakovenko, Sigrun Roesel, Humayun Asghar, Najam Baig, Varja Grabovac, Santosh Gurung, Nicksy Gumede-Moeletsi, Jacob Barnor, Andros Theo, Gloria Rey-Benito, Andrea Villalobos, Liliane Boualam, Joseph Swan, Roland W. Sutter, Ekkehart Pandel, Steven Wassilak, M. Steven Oberste, Ian Lewis, Michel Zaffran
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Among the three wild poliovirus (WPV) types, type 2 (WPV2) was declared eradicated globally by the Global Commission for the Certification of Poliomyelitis Eradication (GCC) in 2015. Subsequently, in 2016, a global withdrawal of Sabin type 2 oral poliovirus vaccine (OPV2) from routine use, through a synchronized switch from the trivalent formulation of oral poliovirus vaccine (tOPV, containing vaccine virus types 1, 2, and 3) to the bivalent form (bOPV, containing types 1 and 3), was implemented. WPV type 3 (WPV3), last detected in 2012 (1), will possibly be declared eradicated in late 2019.* To ensure that polioviruses are not reintroduced to the human population after eradication, World Health Organization (WHO) Member States committed in 2015 to containing all polioviruses in poliovirus-essential facilities (PEFs) that are certified to meet stringent containment criteria; implementation of containment activities began that year for facilities retaining type 2 polioviruses (PV2), including type 2 oral poliovirus vaccine (OPV) materials (2). As of August 1, 2019, 26 countries have nominated 74 PEFs to retain PV2 materials. Twenty-five of these countries have established national authorities for containment (NACs), which are institutions nominated by ministries of health or equivalent bodies to be responsible for poliovirus containment certification. All designated PEFs are required to be enrolled in the certification process by December 31, 2019 (3). When GCC certifies WPV3 eradication, WPV3 and vaccine-derived poliovirus (VDPV) type 3 materials will also be required to be contained, leading to a temporary increase in the number of designated PEFs. When safer alternatives to wild and OPV/Sabin strains that do not require containment conditions are available for diagnostic and serologic testing, the number of PEFs will decrease. Facilities continuing to work with polioviruses after global eradication must minimize the risk for reintroduction into communities by adopting effective biorisk management practices.
TCT-343 Diagnostic Accuracy and Reproducibility of Optical Coherence Tomography–Based Fractional Flow Reserve for Functional Evaluation of Coronary Stenosis
Authors: Shengxian Tu, Jiayue Huang, Hiroki Emori, Wei Yu, Daixin Ding, Takashi Kubo, Miao Chu, Peng Wu, Takashi Akasaka, William Wijns
Journal: Journal of the American College of Cardiology (2019)
Understanding Progressive Fibrosing Interstitial Lung Disease through Therapeutic Trials
Authors: Hilary J. Goldberg
Journal: New England Journal of Medicine (2019)

In the era before antifibrotic therapy, idiopathic pulmonary fibrosis (IPF), the most common of the idiopathic interstitial pneumonias, had a survival rate of 20 to 30% at 5 years,1 a poorer outcome than that of many common forms of cancer. Patients with IPF still have a progressive course that is either gradual and predictable or defined by sudden episodes of acute worsening. The lethality of this disease has stimulated substantial interest in identifying new therapeutic options for its management, with two new therapies showing clinical benefit in the past 5 years.2,3 Similar patterns of decline have also been observed in . . .
Preventing foot ulcers in diabetes using plantar pressure feedback
Authors: Sicco A Bus
Journal: The Lancet Digital Health (2019)

Lower-extremity complications of diabetes are a major burden to patients and society, ranking 10th in leading causes of global disease burden and disability.1 Between 19% and 34% of people with diabetes might develop a foot ulcer in their life.2 These ulcers develop because high mechanical stresses from weight-bearing activity act on an insensate foot. In particular, the risk for ulcer recurrence in diabetes is high.2 To prevent plantar foot ulcer recurrence, international guidelines recommend the use of therapeutic footwear with a demonstrated plantar pressure-relieving effect.
TCT-654 Feasibility and Safety of Intravascular Lithotripsy in Severely Calcified Left Main Coronary Stenoses
Authors: Carlos Salazar, Nieves Gonzalo, Adem Aksoy, Rosa Abellas-Sequeiros, Maria Tovar, Florian Blachutzik, Gabriela Tirado-Conte, Holger Nef, Carlos Gonzalez-Juanatey, Nicolas Van Mieghem, Azeem Latib, Raymundo Ocaranza-Sanchez, Nikos Werner, Javier Escaned
Journal: Journal of the American College of Cardiology (2019)
Injuries of the Peripheral Nerves.
Authors: F Powell Connor
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cognitive Behaviour Therapy Complemented with Emotion Regulation Training for Patients with Persistent Physical Symptoms: A Randomised Clinical Trial
Authors: Maria Kleinstäuber, Christine Allwang, Josef Bailer, Matthias Berking, Christian Brünahl, Maja Erkic, Harald Gitzen, Mario Gollwitzer, Japhia-Marie Gottschalk, Jens Heider, Andrea Hermann, Claas Lahmann, Bernd Löwe, Alexandra Martin, Jörn Rau, Annette Schröder, Johannes Schwabe, Jeanine Schwarz, Rudolf Stark, Frauke Dorothee Weiss, Winfried Rief
Journal: Psychotherapy and Psychosomatics (2019)

&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Persistent medically unexplained symptoms (MUS) are a major burden for health care. Cognitive behaviour therapy (CBT) is efficacious for patients with MUS, with small to medium effects. The current study investigates whether therapy outcomes of a CBT for MUS patients can be improved by complementing it with emotion regulation training. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; In a multicentre trial 255 patients with at least three persisting MUS were randomised to 20 sessions of either conventional CBT (&lt;i&gt;n&lt;/i&gt; = 128) or CBT complemented with emotion regulation training (ENCERT; &lt;i&gt;n&lt;/i&gt; = 127). Somatic symptom severity and secondary outcomes were assessed at pre-treatment, therapy session 8, end of therapy, and 6-month follow-up. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Linear mixed-effect models revealed medium to large effects in both study arms for almost all outcomes at the end of therapy and 6-month follow-up. ENCERT and CBT did not differ in their effect on the primary outcome (&lt;i&gt;d&lt;/i&gt; = 0.20, 95% CI: –0.04 to 0.44). Significant time × group cross-level interactions suggested ENCERT to be of more benefit than conventional CBT for a few secondary outcomes. Moderator analyses revealed higher effects of ENCERT in patients with co-morbid mental disorders. &lt;b&gt;&lt;i&gt;Discussion/Conclusions:&lt;/i&gt;&lt;/b&gt; Current findings are based on a representative sample. Results demonstrate that both CBT and ENCERT can achieve strong effects on primary and secondary outcomes in MUS patients. Our results do not indicate that adding a training in emotion regulation skills generally improves the effect of CBT across all patients with MUS. Large effect sizes of both treatments and potential specific benefits of ENCERT for patients with co-morbid mental disorders are discussed.
TCT-237 Revascularization Options for Women With Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials
Authors: Tayyab Shah, Burcu Gul, Stuart Head, J. Dawn Abbott, Alaide Chieffo, Andreas Baumbach, Xin Hu, Fangyong Li, Alexandria Brackett, Cameron Gesick, Priyanka Bisarya, Roxana Mehran, Cindy Grines, Arnar Geirsson, Julinda Mehilli, Alexandra Lansky
Journal: Journal of the American College of Cardiology (2019)
Abstract 20034: Outcome of Conscious Survivors of Out-of-Hospital Cardiac Arrest
Authors: Eva Slapnik, Martin Rauber, Marko Noc, Peter Radšel
Journal: Circulation (2017)

Background: Only up to 20% of patients with out-of-hospital cardiac arrest (OHCA) receive immediate and optimal initial cardiac resuscitation and consequently regain consciousness soon after reesta...
TCT-382 Technical Issues in 2-Stent Distal Left Main Bifurcation Treatment: An EXCEL Trial Intravascular Ultrasound Substudy
Authors: Tatsuhiro Fujimura, Akiko Maehara, Mitsuaki Matsumura, Adrian Banning, Imre Ungi, Manu Prabhakar, Zixuan Zhang, A. Pieter Kappetein, Joseph Sabik, Patrick Serruys, Gary Mintz, Gregg Stone
Journal: Journal of the American College of Cardiology (2019)
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory irinotecan-naïve advanced colorectal cancer (CRC): dose-finding, pharmacokinetics, safety and efficacy
Authors: T. Hickish, I. Chau, A. Massey, L. Higgins, R. Osborne, N. Botwood, A. Swaisland, D. C. Cunningham
Journal: Journal of Clinical Oncology (2006)

13520 Background: Gefitinib (IRESSA) is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has shown supra-additive activity in human CRC xenografts when combined with irinotecan. We have previously established that the recommended dose level (RDL) to be irinotecan 225mg/m 2 q3 weeks and gefitinib 250mg daily (Chau et al ASCO 2004). The dose limiting toxicities were neutropenia and diarrhoea. The continuation phase of this study aimed to evaluate the efficacy and safety of this combination. Patients and Methods: Between Jun 2002 and Feb 2005, patients (pts) with advanced CRC progressing on or within 12 weeks of fluoropyrimidines-based chemotherapy, irinotecan-naïve and performance status ≤2 were recruited. Thirty-nine pts were treated with irinotecan and gefitinib in total with 27 treated at the RDL. Results: Median age was 61 years (range: 31–79) and 13 (33.3%) pts were females. All pts were Caucasians (94.9%) and non-oriental Asians (5.1%). Thirteen (33.3%) pts had received (neo)adjuvant chemotherapy and 16 (41.0%) pts had prior oxaliplatin-based chemotherapy for metastatic disease. Grades 3–4 toxicities were anaemia 2.6%, neutropenia 15.4%, febrile neutropenia 10.3%, diarrhoea 35.9%, nausea 2.6%, vomiting 5.1%, lethargy 15.4% and skin rash 7.7%. For the pts treated at RDL, the objective tumour response rate was 11.1% (3 partial responses [PRs]; 95% confidence interval [CI]: 2.4–29.2%) and the disease control rate was 40.7% (3PRs, 8 stable diseases lasting for ≥12 weeks). The median time to progression was 4.2 months and median survival was 9.3 months. Six-month progression free survival was 22.2% (95% CI: 6.5–37.9%) and 6-month overall survival was 73.4% (95% CI: 56.5–90.3%). Preliminary pharmacokinetic data suggested that the addition of irinotecan to gefitinib resulted in an average of 14–33% increase in exposure to gefitinib (p&lt;0.05). Conclusions: Irinotecan and gefitinib at this dose schedule was tolerable. Gefitinib did not appear to add substantial efficacy to irinotecan. The relative low dose of irinotecan at the RDL and the rarity of EGFR somatic mutation in CRC may be contributory to the modest activity of irinotecan and gefitinib combination. [Table: see text]
Insomnia and risk of mortality from all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of prospective cohort studies
Authors: Long Ge, Gordon Guyatt, Jinhui Tian, Bei Pan, Yaping Chang, Yajing Chen, Huijuan Li, Junmei Zhang, Yahong Li, Juan Ling, Kehu Yang
Journal: Sleep Medicine Reviews (2019)
CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies
Authors: Hong Qin, Zhenyuan Dong, Xiuli Wang, Wesley A. Cheng, Feng Wen, Weili Xue, Han Sun, Miriam Walter, Guowei Wei, D. Lynne Smith, Xiuhua Sun, Fan Fei, Jianming Xie, Theano I. Panagopoulou, Chun-Wei Chen, Joo Y. Song, Ibrahim Aldoss, Clarisse Kayembe, Luisa Sarno, Markus Müschen, Giorgio G. Inghirami, Stephen J. Forman, Larry W. Kwak
Journal: Science Translational Medicine (2019)

BAFF receptor is a target for CAR T cell therapy of B cell malignancies, circumventing issues with CD19 antigen loss in tumors.
Trends in physical fitness, growth, and nutritional status of Chinese children and adolescents: a retrospective analysis of 1·5 million students from six successive national surveys between 1985 and 2014
Authors: Yanhui Dong, Patrick W C Lau, Bin Dong, Zhiyong Zou, Yide Yang, Bo Wen, Yinghua Ma, Peijin Hu, Yi Song, Jun Ma, Susan M Sawyer, George C Patton
Journal: The Lancet Child & Adolescent Health (2019)
Increasing stepwise expression of p16 e pRb proteins in esophageal mucosa from patients at high risk for squamous cell carcinoma.
Authors: Leandro Bizarro Muller, Luis Carlos Moreira Antunes, Antonio de Barros Lopes, Sara Vanazzi, Luise Meurer, Renato Borges Fagundes
Journal: Journal of Clinical Oncology (2013)

e15067 Background: Squamous cell carcinoma of the esophagus is a lethal cancer which carries a poor prognosis due to late diagnosis. Identification of molecular markers may aid early diagnosis. We assessed the expression of p16 and pRb in esophageal mucosa and their associations with histology. Methods: Esophageal biopsies were collected from 38 patients with no esophageal lesion (group 1); from iodine-negative and normally staining areas from 108 alcoholic smokers (group 2); and from tumor and non-tumor areas from 41 patients with squamous cell carcinoma (group 3). The histological diagnoses were compared with immunoexpression of p16 and pRb (defined as positive staining in &gt;10% of the cells). Results: In group 1, the biopsies showed only normal mucosa or mild esophagitis, and no expression of p16 or pRb. In groups 2 and 3 the diagnoses were: normal mucosa (38.4%); esophagitis (44.4%); dysplasia or carcinoma in situ (2.8%) and carcinoma (14.3%). The percentage of cases with immunoexpression of p16 and pRb increased in a stepwise fashion over the histologic spectrum from normal mucosa to esophagitis, dysplasia/carcinoma in situ and carcinoma (p for trend &lt; 0.01). Conclusions: Esophageal mucosa exposed to alcohol and tobacco which expresses these proteins may be at risk for malignant transformation.
Traction-assisted endoscopic submucosal dissection for a gastric lesion involving the pyloric ring and duodenal bulb
Authors: Marta Rodríguez-Carrasco, Gonçalo Nunes, Diogo Libânio, Pedro Pimentel-Nunes, Mário Dinis-Ribeiro
Journal: Endoscopy (2019)

An 81-year-old woman underwent an upper gastrointestinal endoscopy because of anemia. Two lesions were detected: a 30-mm type 0-Ip located in the lesser curvature of the antrum, and a 25-mm type 0-Is involving the upper hemisphere of the pylorus and the proximal duodenal bulb. Biopsy specimens revealed hyperplastic polyp and adenocarcinoma, respectively. Endoscopic submucosal dissection (ESD) was proposed ([Video 1]).
TCT-625 Coronary Physiologic Parameters and Disconcordance Between Resting Full-Cycle Ratio and FFR-Based Decision Making on Myocardial Revascularization
Authors: Łukasz Niewiara, Bartlomiej Guzik, Piotr Szolc, Wojciech Zajdel, Jacek Legutko
Journal: Journal of the American College of Cardiology (2019)
Ultracompliant Carbon Nanotube Direct Bladder Device
Authors: Dongxiao Yan, Tim M. Bruns, Yuting Wu, Lauren L. Zimmerman, Chris Stephan, Anne P. Cameron, Euisik Yoon, John P. Seymour
Journal: Advanced Healthcare Materials (2019)

Abstract The bladder, stomach, intestines, heart, and lungs all move dynamically to achieve their purpose. A long‐term implantable device that can attach onto an organ, sense its movement, and deliver current to modify the organ function would be useful in many therapeutic applications. The bladder, for example, can suffer from incomplete contractions that result in urinary retention with patients requiring catheterization. Those affected may benefit from a combination of a strain sensor and electrical stimulator to better control bladder emptying. The materials and design of such a device made from thin layer carbon nanotube (CNT) and Ecoflex 00–50 are described and demonstrate its function with in vivo feline bladders. During bench‐top characterization, the resistive and capacitive sensors exhibit stability throughout 5000 stretching cycles under physiology conditions. In vivo measurements with piezoresistive devices show a high correlation between sensor resistance and volume. Stimulation driven from platinum‐silicone composite electrodes successfully induce bladder contraction. A method for reliable connection and packaging of medical grade wire to the CNT device is also presented. This work is an important step toward the translation of low‐durometer elastomers, stretchable CNT percolation, and platinum‐silicone composite, which are ideal for large‐strain bioelectric applications to sense or modulate dynamic organ states.
The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity
Authors: Lori M. Minasian, Eileen Dimond, Myrtle Davis, Bishow Adhikari, Richard Fagerstrom, Carol Fabian, Justin Floyd, Joseph M. Unger, Pamela S. Douglas, Karen M. Mustian, Eric J. Chow, Steven Lipshultz, W. Gregory Hundley, Saro H. Armenian, Bonnie Ky
Journal: JACC CardioOncology (2019)

Cardiovascular (CV) toxicity from cancer therapy is a significant and growing concern. Conventional oncology clinical trial designs focused solely on cancer treatment efficacy have not provided sufficient information on both CV risk factors and outcomes. Similarly, traditional CV trials evaluating standard interventions typically exclude cancer patients, particularly those actively receiving cancer therapy. Neither trial type simultaneously evaluates the balance between CV toxicity and cancer outcomes; however, there is increasing collaboration among oncologists and cardiologists to design new cardio-oncology trials that address this important need. In this review, we detail 5 ongoing, oncology-based trials with integrated CV endpoints. Key design features include: 1) a careful assessment of CV risk factors and disease before, during, and after cancer therapy with standardized collection of clinical imaging, functional, and biomarker data; 2) an introduction of cardioprotective interventions at various timepoints in cancer therapy; 3) a balance of the risk of subclinical CV injury with the need for ongoing cancer treatment; and 4) an understanding of the time profile for development of clinically apparent CV toxicity. Additional critical priorities in cardio-oncology clinical research include harmonization of data collection and definitions for all physician- and patient-reported exposures and outcomes.
The Frequency of Primary Immune Thrombocytopenia (idiopathic thrombocytopenic purpura) in Patients with Isolated Thrombocytopenia
Authors: Anait L. Melikyan, Elena K Egorova, Elena I Pustovaya, Tamara I Kolosheynova, Irina N Subortseva, Elena A Gilyazitdinova, Valeriy G. Savchenko
Journal: Blood (2018)
TCT-754 Transcatheter Aortic Valve Replacement in Very Large Annuli With the 34mm Self-Expanding CoreValve® Evolut R: Prospective Multicentre Registry
Authors: Victor Alfonso Jimenez Diaz, Diego López Otero, Ignacio Cruz-Gonzalez, Ignacio Amat-Santos, Fernando Rivero, Enrique Gutierrez Ibanes, Antonio Munoz-Garcia, Beatriz Vaquerizo, Jose Carlos Moreno Samos, Tania Rodriguez Gabella, Hugo Gonzalez Saldivar, Ramiro Trillo Nouche, Jose Antonio Baz Alonso, Andres Iñiguez
Journal: Journal of the American College of Cardiology (2019)
TCT-239 Impact of Nonrespect of SYNTAX Score II Recommendations for Surgery in Patients With Complex Coronary Artery Disease Treated by PCI: A Pooled Analysis of 3,280 Randomized Patients: SYNTAX, BEST, and PRECOMBAT Trials
Authors: Patrick Serruys, Rodrigo Modolo, Ply Chichareon, Norihiro Kogame, Chun-Chin Chang, Mariusz Tomaniak, Kuniaki Takahashi, Jung-Min Ahn, Yoshinobu Onuma, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2019)
TCT-404 Benefit and Risks of Aspirin on Top of Ticagrelor in Acute Coronary Syndromes: Insights From the Randomized GLOBAL LEADERS Trial
Authors: Mariusz Tomaniak, Ply Chichareon, Yoshinobu Onuma, Efthymios Deliargyris, Kuniaki Takahashi, Norihiro Kogame, Rodrigo Modolo, Chun-Chin Chang, Tessa Rademaker-Havinga, Robert Storey, George Dangas, Deepak Bhatt, Dominick Angiolillo, Christian Hamm, Marco Valgimigli, Stephan Windecker, Philippe Gabriel Steg, Pascal Vranckx, Patrick Serruys
Journal: Journal of the American College of Cardiology (2019)
TCT-88 6-Month Outcomes of an Early Feasibility Study of the AccuCinch Left Ventricular Repair System in Patients With Heart Failure and Functional Mitral Regurgitation
Authors: Mark Reisman, James Wudel, Steven Martin, Hosakote Nagaraj, Guilherme Silva, Don Creigthon, Kendra Grubb, Hemal Gada, Paul Sorajja, Susheel Kodali, Brian Whisenant, Pradeep Yadav, Nadira Hamid, Daniel Burkhoff
Journal: Journal of the American College of Cardiology (2019)